Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals.
Iwamoto T, Nozaki Y, Inoue T, Suda T, Mizumoto R, Arimoto Y, Ohta T, Yamaguchi S, Ito Y, Sudo Y, Yoshimura M, Kai M, Sasaki Y, Tahata Y, Hikita H, Takehara T, Hagiwara H. Iwamoto T, et al. Among authors: hikita h. J Gastroenterol. 2024 Nov 25. doi: 10.1007/s00535-024-02165-0. Online ahead of print. J Gastroenterol. 2024. PMID: 39585387
Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan.
Hagiwara H, Ito Y, Ohta T, Nozaki Y, Iwamoto T, Hosui A, Hiramatsu N, Tahata Y, Sakamori R, Hikita H, Hayashi N. Hagiwara H, et al. Among authors: hikita h. JGH Open. 2022 May 18;6(6):395-401. doi: 10.1002/jgh3.12745. eCollection 2022 Jun. JGH Open. 2022. PMID: 35774345 Free PMC article.
The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin.
Tahata Y, Hiramatsu N, Oze T, Morishita N, Harada N, Yamada R, Yakushijin T, Mita E, Hagiwara H, Yamada Y, Ito T, Hijioka T, Inada M, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Irishio K, Kato M, Hikita H, Sakamori R, Miyagi T, Yoshida Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T. Tahata Y, et al. Among authors: hikita h. J Gastroenterol. 2016 Mar;51(3):252-9. doi: 10.1007/s00535-015-1105-9. Epub 2015 Jul 30. J Gastroenterol. 2016. PMID: 26223482 Clinical Trial.
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response.
Yamada R, Hiramatsu N, Oze T, Urabe A, Tahata Y, Morishita N, Kodama T, Hikita H, Sakamori R, Yakushijin T, Yamada A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Inui Y, Hijioka T, Inada M, Katayama K, Tamura S, Inoue A, Imai Y, Tatsumi T, Hamasaki T, Hayashi N, Takehara T. Yamada R, et al. Among authors: hikita h. Hepatol Res. 2019 May;49(5):570-578. doi: 10.1111/hepr.13310. Epub 2019 Feb 6. Hepatol Res. 2019. PMID: 30623521
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Tahata Y, Hikita H, Mochida S, Kawada N, Enomoto N, Ido A, Yoshiji H, Miki D, Hiasa Y, Takikawa Y, Sakamori R, Kurosaki M, Yatsuhashi H, Tateishi R, Ueno Y, Itoh Y, Yamashita T, Kanto T, Suda G, Nakamoto Y, Kato N, Asahina Y, Matsuura K, Terai S, Nakao K, Shimizu M, Takami T, Akuta N, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: hikita h. J Gastroenterol. 2021 Jan;56(1):67-77. doi: 10.1007/s00535-020-01733-4. Epub 2020 Oct 1. J Gastroenterol. 2021. PMID: 33001338 Clinical Trial.
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.
Maesaka K, Sakamori R, Yamada R, Tahata Y, Oshita M, Hagiwara H, Sakakibara M, Tamura S, Hiramatsu N, Inada M, Iio S, Ito T, Yakushijin T, Doi Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: hikita h. Hepatol Res. 2021 May;51(5):517-527. doi: 10.1111/hepr.13623. Epub 2021 Mar 9. Hepatol Res. 2021. PMID: 33507588
Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: hikita h. J Gastroenterol. 2022 Feb;57(2):120-132. doi: 10.1007/s00535-021-01845-5. Epub 2022 Jan 20. J Gastroenterol. 2022. PMID: 35059853
331 results